Literature DB >> 12086849

Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis.

Theresa Lopez1, Douglas Hanahan.   

Abstract

In a prototypical model of multistage tumorigenesis involving pancreatic islets in RIP1-Tag2 transgenic mice, activation of insulin-like growth factor II (IGF-II) was previously shown to serve as a survival factor that inhibited apoptosis. Now IGF-1R, the receptor tyrosine kinase for IGF-II, has been found to be variably upregulated, first uniformly in dysplastic and angiogenic progenitors and then focally at the margins and in invasive regions of carcinomas. When the levels of IGF-1R were forcibly elevated throughout islet tumorigenesis, progression was accelerated at all stages in the pathway, although apoptosis was not differentially suppressed. Notably, encapsulated tumors were absent; instead, invasive carcinomas with downregulated E-cadherin were prevalent, and the majority of mice had local lymph node metastasis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12086849     DOI: 10.1016/s1535-6108(02)00055-7

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  100 in total

Review 1.  Sunitinib in pancreatic neuroendocrine tumors.

Authors:  Eric Raymond; Pascal Hammel; Chantal Dreyer; Christian Maatescu; Olivia Hentic; Philippe Ruszniewski; Sandrine Faivre
Journal:  Target Oncol       Date:  2012-06-02       Impact factor: 4.493

Review 2.  Involvement of members of the cadherin superfamily in cancer.

Authors:  Geert Berx; Frans van Roy
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-09-23       Impact factor: 10.005

3.  Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy.

Authors:  Danielle B Ulanet; Dale L Ludwig; C Ronald Kahn; Douglas Hanahan
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-10       Impact factor: 11.205

4.  Identification and pre-clinical testing of a reversible cathepsin protease inhibitor reveals anti-tumor efficacy in a pancreatic cancer model.

Authors:  Benelita Tina Elie; Vasilena Gocheva; Tanaya Shree; Stacie A Dalrymple; Leslie J Holsinger; Johanna A Joyce
Journal:  Biochimie       Date:  2010-05-04       Impact factor: 4.079

5.  Northwestern profiling of potential translation-regulatory proteins in human breast epithelial cells and malignant breast tissues: evidence for pathological activation of the IGF1R IRES.

Authors:  Scott W Blume; Nateka L Jackson; Andra R Frost; William E Grizzle; Oleg D Shcherbakov; Hyoungsoo Choi; Zheng Meng
Journal:  Exp Mol Pathol       Date:  2010-03-15       Impact factor: 3.362

6.  Dopamine, by acting through its D2 receptor, inhibits insulin-like growth factor-I (IGF-I)-induced gastric cancer cell proliferation via up-regulation of Krüppel-like factor 4 through down-regulation of IGF-IR and AKT phosphorylation.

Authors:  Subhalakshmi Ganguly; Biswarup Basu; Saurav Shome; Tushar Jadhav; Sudipta Roy; Jahar Majumdar; Partha Sarathi Dasgupta; Sujit Basu
Journal:  Am J Pathol       Date:  2010-11-12       Impact factor: 4.307

Review 7.  A new link between epigenetic progenitor lesions in cancer and the dynamics of signal transduction.

Authors:  Winston Timp; Andre Levchenko; Andrew P Feinberg
Journal:  Cell Cycle       Date:  2009-02-03       Impact factor: 4.534

8.  Development of targeted therapy for a broad spectrum of solid tumors mediated by a double promoter plasmid expressing diphtheria toxin under the control of IGF2-P4 and IGF2-P3 regulatory sequences.

Authors:  Doron Amit; Sagi Tamir; Abraham Hochberg
Journal:  Int J Clin Exp Med       Date:  2013-01-26

Review 9.  Insights into the Link Between Obesity and Cancer.

Authors:  Sarah E Ackerman; Olivia A Blackburn; François Marchildon; Paul Cohen
Journal:  Curr Obes Rep       Date:  2017-06

10.  Clinical pathological characteristics and prognostic analysis of diabetic women with luminal subtype breast cancer.

Authors:  Yuanting Xiao; Sheng Zhang; Guofang Hou; Xiaobei Zhang; Xiaomeng Hao; Jin Zhang
Journal:  Tumour Biol       Date:  2013-10-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.